These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 31769617

  • 1. Revisiting Bromohexitols as a Novel Class of Microenvironment-Activated Prodrugs for Cancer Therapy.
    Johansson H, Hussain O, Allison SJ, Robinson TV, Phillips RM, Sejer Pedersen D.
    ChemMedChem; 2020 Jan 17; 15(2):228-235. PubMed ID: 31769617
    [Abstract] [Full Text] [Related]

  • 2. Novel hypoxia-targeting Pt(iv) prodrugs.
    Xu Z, Zhao J, Gou S, Xu G.
    Chem Commun (Camb); 2017 Mar 28; 53(26):3749-3752. PubMed ID: 28303266
    [Abstract] [Full Text] [Related]

  • 3. Design, synthesis and evaluation of targeted hypoxia-activated prodrugs applied to chondrosarcoma chemotherapy.
    Gerard Y, Voissière A, Peyrode C, Galmier MJ, Maubert E, Ghedira D, Tarrit S, Gaumet V, Canitrot D, Miot-Noirault E, Chezal JM, Weber V.
    Bioorg Chem; 2020 May 28; 98():103747. PubMed ID: 32208207
    [Abstract] [Full Text] [Related]

  • 4. Dual targeting of hypoxic and acidic tumor environments with a cobalt(III) chaperone complex.
    Yamamoto N, Renfrew AK, Kim BJ, Bryce NS, Hambley TW.
    J Med Chem; 2012 Dec 27; 55(24):11013-21. PubMed ID: 23199008
    [Abstract] [Full Text] [Related]

  • 5. Synthesis, bioconversion, pharmacokinetic and pharmacodynamic evaluation of N-isopropyl-oxy-carbonyloxymethyl prodrugs of CZh-226, a potent and selective PAK4 inhibitor.
    Guo J, Wang T, Wu T, Zhang K, Yin W, Zhu M, Pang Y, Hao C, He Z, Cheng M, Liu Y, Zheng J, Gu J, Zhao D.
    Eur J Med Chem; 2020 Jan 15; 186():111878. PubMed ID: 31757524
    [Abstract] [Full Text] [Related]

  • 6. Development and biological investigations of hypoxia-sensitive prodrugs of the tyrosine kinase inhibitor crizotinib.
    Bielec B, Schueffl H, Terenzi A, Berger W, Heffeter P, Keppler BK, Kowol CR.
    Bioorg Chem; 2020 Jun 15; 99():103778. PubMed ID: 32229347
    [Abstract] [Full Text] [Related]

  • 7. Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer.
    Tokay E, Güngör T, Hacıoğlu N, Önder FC, Gülhan ÜG, Tok TT, Çelik A, Ay M, Köçkar F.
    Eur J Med Chem; 2020 Feb 01; 187():111937. PubMed ID: 31841727
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Synthesis and biological evaluation of paclitaxel and vorinostat co-prodrugs for overcoming drug resistance in cancer therapy in vitro.
    Liu S, Zhang K, Zhu Q, Shen Q, Zhang Q, Yu J, Chen Y, Lu W.
    Bioorg Med Chem; 2019 Apr 01; 27(7):1405-1413. PubMed ID: 30819618
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Synthesis and one-electron reduction characteristics of radiation-activated prodrugs possessing two 5-fluorodeoxyuridine units.
    Tanabe K, Sugiura M, Ito T, Nishimoto S.
    Bioorg Med Chem; 2012 Sep 01; 20(17):5164-8. PubMed ID: 22847019
    [Abstract] [Full Text] [Related]

  • 14. Ruthenium Complexes are pH-Activated Metallo Prodrugs (pHAMPs) with Light-Triggered Selective Toxicity Toward Cancer Cells.
    Qu F, Park S, Martinez K, Gray JL, Thowfeik FS, Lundeen JA, Kuhn AE, Charboneau DJ, Gerlach DL, Lockart MM, Law JA, Jernigan KL, Chambers N, Zeller M, Piro NA, Kassel WS, Schmehl RH, Paul JJ, Merino EJ, Kim Y, Papish ET.
    Inorg Chem; 2017 Jul 03; 56(13):7519-7532. PubMed ID: 28636344
    [Abstract] [Full Text] [Related]

  • 15. A Novel Tumor-Activated Prodrug Strategy Targeting Ferrous Iron Is Effective in Multiple Preclinical Cancer Models.
    Spangler B, Fontaine SD, Shi Y, Sambucetti L, Mattis AN, Hann B, Wells JA, Renslo AR.
    J Med Chem; 2016 Dec 22; 59(24):11161-11170. PubMed ID: 27936709
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. ROS-sensitive biomimetic nanocarriers modulate tumor hypoxia for synergistic photodynamic chemotherapy.
    Liu H, Jiang W, Wang Q, Hang L, Wang Y, Wang Y.
    Biomater Sci; 2019 Aug 20; 7(9):3706-3716. PubMed ID: 31187794
    [Abstract] [Full Text] [Related]

  • 18. Hypoxia activated prodrugs of a 9-aza-anthrapyrazole derivative that has promising anticancer activity.
    El-Dakdouki MH, Adamski N, Foster L, Hacker MP, Erhardt PW.
    J Med Chem; 2011 Dec 08; 54(23):8224-7. PubMed ID: 22011244
    [Abstract] [Full Text] [Related]

  • 19. Monochalcoplatin: An Actively Transported, Quickly Reducible, and Highly Potent PtIV Anticancer Prodrug.
    Ma L, Wang N, Ma R, Li C, Xu Z, Tse MK, Zhu G.
    Angew Chem Int Ed Engl; 2018 Jul 16; 57(29):9098-9102. PubMed ID: 29806087
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.